Peptomyc announces the approval of its Phase 1b trial testing OMO-103 in combination with standard of care in PDAC patients27 / 07 / 23|
Results from phase I clinical trial of the first drug to successfully inhibit the MYC protein, which drives many common cancers01 / 11 / 22|
Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial28 / 10 / 22|
TODAY in El Mundo: “Así avanza el fármaco español pionero en su estrategia contra el cáncer”26 / 10 / 22|
TODAY in La Vanguardia: “Èxit del primer assaig en pacients del fàrmac Omomyc contra el càncer”26 / 10 / 22|
MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding21 / 02 / 22|
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial06 / 05 / 21|
